Novartis AG Joins GlaxoSmithKline And Gets Over Its Fear Of Heights

Published: Jun 05, 2017

Novartis' (NYSE:NVS) efforts to refocus investors away from its problem areas continued yesterday, with executives plugging its pipeline hopes and predicting a new growth phase from 2018. At an annual investor presentation the Swiss firm unveiled a table of 11 future blockbusters that it believes will drive this, though sellside forecasts suggest that a number still have much to prove (see table below).

Back to news